ArticleJournal of comparative effectiveness research2012
Anti-VEGF therapies for the treatment of age-related macular degeneration.
Article in Journal of comparative effectiveness research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evaluation of: Martin DF, Maguire MG, Fine SL et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration two-year results. Ophthalmology 119(7), 1388-1398 (2012). Age-related macular degeneration is the leading cause of blindness in European-derived populations. Recently, drugs have been developed that not only reduce the risk of vision loss, but can actually improve visual acuity. This article provides a summary of a recent comparative effectiveness trial evaluating two of these drugs. The study found that visual acuity outcomes were similar for the two drugs and that monthly dosing provided a slight advantage over as-needed treatment. The role of long-term differences in retinal thickening, geographic atrophy and potential differences in serious adverse events between the two drugs need further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.